drugset / Trial / NCT04580147
Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Retinal Detachment Repair
Phase 2
Unknown
150 enrolled
M. Ali Khan, MD
Eye Associates of New Mexico · collabSoutheastern Retina Associates · collabUniversity of California, Los Angeles · collab
RandomizedSingle-groupDouble-blindPrevention
Summary
The primary objective of the study is to determine if serial intravitreal aflibercept injections (IAI) improve the single surgery anatomic success rate following surgical repair of primary, macula involving rhegmatogenous retinal detachment (RRD) deemed at high risk for proliferative vitreoretinopathy (PVR). Preclinical work has revealed that competitive inhibition of platelet derived growth factor (PDGF) by vascular endothelial growth factor (VEGF) potentiates a pathologic, sustained activation of PDGF receptors that is critical to the progression of experimental PVR. VEGF blockade would mitigate this pathologic activation.
Timeline
- Start
- 2020-10-15
- Primary completion
- 2023-09-15
- Completion
- 2023-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |